by The global non opioid pain treatment market comprises of products such as pharmaceutical therapies like nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, antidepressants, anticonvulsants, topical analgesics and neurostimulation devices. These products are utilized to treat different types of pain like musculoskeletal pain, neuropathic pain, fibromyalgia and others without using opioids. The popularity of non opioid pain treatments has grown significantly owing to risk of opioid addiction and overdoses. Neurostimulation technology used in products like transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation and deep brain stimulation have advanced and become more effective in pain management.
The Global non opioid pain treatment market is estimated to be valued at US$ 43.67 Bn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the global non opioid pain treatment are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Fresenius Kabi AG, GSK, Vertex Pharmaceuticals Incorporated, Pacira BioSciences, Collegium Pharmaceuticals, Cara Therapeutics, Akelos, Fidia Farmaceutici S.p.A., Sanofi, Eli Lilly and Company and Merck Co.
The key opportunities in the market include entry of new drugs with novel mechanisms of actions and rising adoption of neurostimulation devices. Companies are also investing heavily in research and development of new Non Opioid Pain Treatments Growth.
Advancements in neurostimulation technology like use of smart algorithms and wireless capabilities have made treatments more targeted and effective. Developments in biological therapies like cannabinoids and gene therapies also offer promising alternative to opioids.
Market Drivers
Rising geriatric population vulnerable to chronic pain driving demand for non opioid therapies. Growing awareness about risks of opioid addiction and overdoses is compelling healthcare professionals and patients to consider non opioid options for pain management. Regulatory support to develop safer alternatives to opioids is also boosting investments in this market.
Current Challenges in Non Opioid Pain Treatment Market
The Non-Opioid Pain Treatment Market Challenges And Opportunities is still in a nascent stage. Some of the key challenges include availability of limited treatment options, lack of awareness about alternatives to opioid therapies and high costs associated with new therapies. Many non-opioid drugs currently available have side effects like gastrointestinal issues, liver toxicity etc. which limits their usage. Development of safer and more effective alternatives continues to be an area of focus for pharmaceutical companies.
SWOT Analysis
Strength: Growing prevalence of chronic pain conditions like arthritis, lower back pain etc. driving demand.
Weakness: Narrow therapeutic window and side effects of existing drugs. R&D costs of developing novel non-opioid therapies are high.
Opportunity: Increasing focus on developing non-addictive alternatives to opioids presents significant commercial opportunities. Rising awareness about dangers of opioids widening the market.
Threats: Intense competition from existing opioid analgesics still preferred by doctors and patients due to better efficacy and cost benefits. Regulatory hurdles for new molecules.
Geographical Regions with Highest Market Concentration
North America accounts for the largest share of the global non-opioid pain treatment market, both in terms of value and volume. This is attributed to high incidence of chronic pain disorders, favourable reimbursements and greater accessibility to new treatment alternatives in the region.
Fastest Growing Geographical Region
Asia Pacific region is poised to witness the highest growth during the forecast period owing to rising healthcare expenditure, large patient pool, increasing focus on management of chronic pain etc. China, India and other Asian countries present lucrative opportunities for players in the non-opioid pain treatment market
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it
About Author - Alice Mutum
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights. LinkedIn
